Objective: To investigate the effect of probiotic capsules on plasma lipids. Design: A randomized, single-blinded, placebo-controlled, parallel-arm trial. Subjects: Fifty-five normocholesterolemic subjects ages 18-36 (33 premenopausal women and 22 men). Intervention: Each subject consumed either three probiotic capsules each containing a total of 10 9 colony-forming units Lactobacillus acidophilus and Bifidobacterium longum and 10-15 mg fructo-oligosaccharide or three placebo capsules daily for 2 months (men) or two menstrual cycles (women). Plasma lipids were measured before and following the intervention (during the early follicular phase for women). Results: Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride were not altered by consumption of probiotic or placebo capsules and were not different between treatment groups following the intervention. Conclusions: These results do not support a beneficial effect of Lactobacillus acidophilus strain DDS-1 and Bifidobacterium longum strain UABL-14 on plasma lipids in normocholesterolemic young women and men. Sponsorship: Supported by the Minnesota Agricultural Experiment Station and UAS Laboratories.
Introduction
Coronary heart disease (CHD) is a leading cause of disability and death in industrialized countries. Epidemiological and clinical investigations have demonstrated a positive association between plasma total cholesterol (TC) concentration and CHD risk; in addition, a decrease in plasma cholesterol has been shown to result in reduction of risk (Lipid Research Clinics Program, 1984; Castelli, 1986; Scandinavian Simvastatin Study Group, 1994) . Numerous pharmacological and dietary approaches have been proposed to achieve this cholesterol reduction, including the administration of probiotic bacteria.
Probiotic bacteria have been defined as 'live microorganisms, which when consumed in adequate amounts, confer a health effect on the host' (Guarner and Schaafsma, 1998) . In addition to their purported hypocholesterolemic effect, these bacteria have been hypothesized to enhance the immune response, treat antibiotic or travelers diarrhea, improve gastrointestinal (GI) health and reduce fecal enzymes implicated in cancer initiation (Kaur et al., 2002) . Probiotic bacteria are incorporated into dairy foods such as milk and yogurt or packaged as capsules for human consumption. Probiotic products are widely available in Europe, Japan and the US through direct sales, supermarkets, drug stores and health food stores; over $67 million was spent in the US on probiotics in 1999 (Sanders, 1998; Madley, 2001) . Species within the Lactobacillus and Bifidobacterium genera are the most commonly used probiotics, although probiotic qualities have also been ascribed to Enterococcus faecium and Streptococcus thermophilus.
In vitro experiments have suggested several mechanisms for the cholesterol-lowering effect of probiotic bacteria such as L. acidophilus and Bifidobacterium Bacteria may directly remove cholesterol by incorporating it into the bacterial cell membrane, binding cholesterol to the cell surface or assimilating cholesterol during growth (Noh et al., 1997; Brashears et al., 1998; Liong and Shah, 2005) . In addition, bacteria may produce bile salt hydrolase and deconjugate bile acids. The resulting bile acids co-precipitate with cholesterol and are excreted in the feces, thereby reducing cholesterol through fecal excretion and through the synthesis of additional bile acids from cholesterol (Klaver and van der Meer, 1993; Brashears et al., 1998; Tanaka et al., 1999) .
The majority of studies examining the effect of probiotic bacteria on plasma lipids have employed fermented milk products as the vehicle of administration. Although most studies have reported a hypocholesterolemic effect (Agerback et al., 1995; Schaafsma et al., 1998; Bertolami et al., 1999; Xiao et al., 2003) , not all investigations support this result (Richelsen et al., 1996; de Roos et al., 1999) . The logistics of procuring and storing a fermented milk product for daily consumption and the dietary modification required to accommodate the additional calories contained in fermented milk products have prompted an exploration of alternative methods for ingesting probiotic bacteria.
Capsules containing freeze-dried probiotic bacteria are a more convenient and calorie-free medium with a refrigerated shelf life of up to 12 months. Probiotic capsules and lipids have been examined in several human studies, but with conflicting results. An initial pilot trial (Lin et al., 1989) and an open-label study (Mohan et al., 1990) produced promising decreases in plasma TC and low-density lipoprotein cholesterol (LDL-C). However, with the exception of one recent investigation (Hlivak et al., 2005) , blinded-and placebocontrolled investigations (Lin et al., 1989; Lewis and Burmeister, 2005) have not demonstrated a hypocholesterolemic effect of probiotic bacteria in capsule form. Therefore, the objective of this investigation was to clarify the effect of probiotic bacteria administered in capsule form on plasma lipid concentrations.
Materials and methods

Subjects
This study was part of a larger investigation examining the effects of probiotic consumption on equol excretion and plasma hormone concentrations. Healthy men and premenopausal women age 18-36 years were recruited from the Minneapolis/St Paul metropolitan area and enrolled in the study after a telephone screening and review of a detailed self-administered questionnaire. Exclusionary criteria included BMI o18 or 430 kg/m 2 , weight change of more than 4.5 kg within the previous year or more than 2.3 kg within the previous 2 months, antibiotic or exogenous hormone use within the last 3 months, probiotic supplement use within the last 30 days, alcohol consumption greater than seven drinks/week, chronic health problems, regular medication use and for the women menstrual cycles o24 or 432 days and current pregnancy or lactation. Minimum or maximum lipid concentrations were not part of the exclusion criteria; however, all subjects completing the study were normocholesterolemic. The Institutional Review Board: Human Subjects Committee of the University of Minnesota approved the study protocol. All subjects provided written, informed consent before participation in the study.
Experimental design and diet Two-thirds of the subjects were randomized to receive probiotic and one-third randomized to receive placebo capsules in a single blind, parallel-arm design. Following baseline data collection on day 1, men consumed capsules from study day 5 until day 57 (52 days total). Baseline data were obtained from women on days 2, 3 or 4 of menstrual cycle one and capsules consumed from cycle one day 8 until cycle three days 2, 3 or 4 (approximately 52 days). Subjects were free living and were instructed to maintain their habitual physical activity and eating patterns as before the study (with the exception of excluding fermented foods during the study). Subjects consumed three placebo-or probiotic-containing capsules each morning on an empty stomach. Each probiotic capsule contained approximately 1.25 Â 10 9 colony-forming units (CFU) of L. acidophilus strain DDS-1 and 1.25 Â 10 9 CFU of B. longum strain UABL-14 plus 10-15 mg fructo-oligosaccharide in a rice starch base (UAS Laboratories; Minnetonka, MN, USA). The manufacturer's suggested dose was two capsules daily; three capsules were administered in this study in an effort to detect any effect on cholesterol. The placebo capsules (Gallipot Inc.; St Paul, MN, USA) were of similar size, shape and packaging as the probiotic capsules but contained only rice starch. Microbiological evaluations of the probiotic and placebo capsules were conducted at the beginning and midpoint of the study to verify bacterial content.
Data collection
Blood samples were obtained after a 12-14 h fast on days 1 and 57 for the men and during the early follicular phase (days 2, 3 or 4) of menstrual cycles one and three for the women. Samples were drawn between 0600 and 1000 h; preand post-treatment samples for an individual subject were obtained at the same time730 min. Blood was drawn into tubes containing ethylenediaminetetraacetic acid and plasma separated by centrifugation for 10 min at 51C and 2000 Â g. Aprotonin and sodium azide were added to final concentrations of 1 mg/l and 1 g/l, respectively, and aliquots frozen at À701C until analysis. At both visits, subject height and weight (clothed in a hospital gown) were measured and dietary data collected using the health habits and history questionnaire (Block et al., 1986) . This 100-item food frequency questionnaire incorporates portion sizes and proportional nutrient content into the final analysis and includes items such as yogurt to assist in monitoring subject adherence to dietary restrictions. Compliance with study restrictions and capsule consumption was also monitored via daily documentation by subjects on individualized study calendars and end-study count of returned capsules.
Sample analysis
Plasma concentrations of TC and triglyceride (TG) were determined using commercially available reagents (cholesterol/HP and triglyceride/GB; Roche Diagnostics, Indianapolis, IN, USA) with an enzymatic colorimetric method previously adapted for microtiter plates (Carr et al., 1993) . Cholesterol standards were prepared as dilutions of a stock solution (Cholesterol Calibrator 200 mg/dl; Sigma Chemical, St Louis, MO, USA) and TG standards were created from a stock solution of oil with t-octylphenoxypolyethoxyethanol added for solubility (Triton X-100, Sigma Chemical, St Louis, MO, USA). High-density lipoprotein cholesterol (HDL-C) was isolated by selective precipitation of apo B-containing lipoproteins with phosphotungstic acid (6.1 mmol/l; Fischer Scientific, Pittsburgh, PA, USA) and magnesium chloride (20 mmol/l; Fischer Scientific, Pittsburgh, PA, USA). The resulting supernatant was analyzed for cholesterol content using the plasma cholesterol enzymatic assay. LDL-C was calculated using the Friedewald equation (Friedewald et al., 1972) : LDL-C ¼ TCÀHDL-CÀ(TG/5) with all end points expressed as mg/dl. Both samples from a subject were assayed in duplicate on the same day with a high and a low in-house plasma control and a standard curve on each plate. Plates were incubated at room temperature for 60 min before being read at 490 nm with an automated microplate reader (HTS-7000 Plus; Perkin Elmer Corporation, Norwalk, CT, USA). Interassay and intraassay variability were 1-2% for TC, HDL-C and TG.
Food frequency questionnaires were analyzed with DietSys Software version 4.0 (National Cancer Institute, Bethesda, MD, USA) to estimate energy, dietary fiber, macronutrient and micronutrient content.
Statistical analysis
Statistical analysis was performed using the Statistical Analysis System (SAS Institute Inc., Cary, NC, USA) version 8.2 and SPSS version 12.0 (SPSS Inc., Chicago). Comparisons of baseline anthropometrics and lipids between placebo and control groups (for all subjects and for men and women separately) were made using independent t-tests.
Within-group baseline vs end-of-study changes in lipids and dietary intake were evaluated with paired t-tests. Analysis of covariance was used to screen for an interaction between gender and capsule group, assess differences in end-of study lipid concentrations between groups and assess differences in baseline vs end-of-study change in lipids and dietary intake between groups.
Owing to the significant difference between probiotic and placebo groups in baseline HDL-C, between-group comparisons including HDL-C were performed with and without adjustment for baseline HDL-C concentration and both values reported. All between-group analyses were performed with and without adjustment for body weight. However, body weight adjustment had a negligible effect on values and did not alter significance; therefore unadjusted values are reported. Data are presented as mean 7 s.d. P-values less than 0.05 were considered significant.
Results
Subjects
A total of 55 (33 women, 22 men) of the 64 subjects who began the intervention completed all study requirements and provided end-study data. Five men and three women dropped out during the study owing to time conflicts or difficulty adhering to the dietary restrictions and/or sample collection requirements. The demographic characteristics of dropouts were not different than subjects who completed the study. In addition, one woman experienced a 20-day menstrual cycle during the study and was not included in the analyses. The 55 subjects completing the study included 39 (71%) Caucasian, eight (14%) Asian, two (4%) Hispanic, two (4%) African American, one (2%) East Indian and three (5%) mixed racial background. Food frequency questionnaires, subject completion of recording calendars and endstudy capsules counts suggested that compliance with capsule consumption and study restrictions was excellent.
Plasma lipids
Baseline TC, LDL-C and TG were not different between the probiotic and placebo groups (Table 1) . However, despite a similar proportion of men and women in each treatment group, body weight tended to be higher and HDL-C lower in the probiotic group. These differences appear to be influenced by characteristics of the women more than the men. There were no significant baseline to end-of-study changes in any lipid variable within either group; these changes were not significantly different when compared between groups (Table 2) . When change was expressed as percent difference, there were no significant differences between groups for any of these percent difference variables. Unadjusted HDL-C was higher at end-of-study in the placebo group; this difference was eliminated after adjustment for baseline HDL-C. TC, LDL-C and TG were not different between probiotic and placebo groups at end-of-study. TC/HDL-C and LDL-C/HDL-C ratios (using unadjusted and adjusted HDL-C concentrations) were not different between groups at baseline or end-of-study. There were no significant baseline to end-ofstudy changes in these ratios within either group. There were no interactions between gender and capsule group; that is, men and women responded similarly to probiotic treatment.
Dietary intake
There were no changes in consumption of carbohydrate, cholesterol or fiber in either group between baseline and end-of-study. Consumption of energy, protein, fat and saturated fat decreased significantly between baseline and end-of-study in the probiotic group and tended to decrease in a similar magnitude in the placebo group. However, these results are limited by the sensitivity of our dietary assessment tool (food frequency questionnaire). Any decrease in these nutrients would not have masked a change in lipids but would have contributed to a change. None of the observed changes were significantly different between the groups and were unlikely to have been a factor in the lack of significant differences in lipid concentrations during the study.
Discussion
This investigation did not demonstrate a reduction in plasma lipid concentrations following consumption of L. acidophilus DDS-1 and B. longum strain UABL-14 capsules. The lack of an effect may be a result of the clinical characteristics of the subjects, the dose, mode, length, and frequency of administration of probiotics and the specific properties of these bacterial species/strains.
The subjects in the present study were young adults, free from chronic disease and normocholesterolemic (TC o5.17 mmol/l). The results of recent studies providing either capsules or fermented milk suggest that the hypocholesterolemic effect of probiotic bacteria may be related to baseline cholesterol concentration. Investigations demonstrating a hypocholesterolemic effect have generally been conducted in subjects with moderately elevated (46.0 mmol/l) baseline TC (Agerback et al., 1995; Bertolami et al., 1999; Xiao et al., 2003; Hlivak et al., 2005) with the exception of one study with a mean TC of 5.2 mmol/l that included 9 g of fructo-oligosaccharide (a potentially hypocholesterolemic ingredient) in the fermented milk. In contrast, baseline TC in studies that did not show a hypocholesterolemic effect tended to be lower (o5.4 mmol/l) (de Roos et al., 1999; Greany et al., 2004) although a recent investigation in subjects with a mean TC of 6.6 mmol/l (Lewis and Burmeister, 2005 ) also failed to document a lipid-lowering effect.
Although the clinical characteristics of subjects in the present study may have contributed to the lack of change observed in plasma lipids, other dietary substances (such as soy protein) have been shown to improve plasma lipids in young normocholesterolemic subjects (Wong et al., 1998; Merz-Demlow et al., 2000; McVeigh et al., 2006) . In addition, prospective studies have reported a relationship between lipid concentrations within the normal range and future CHD (Klag et al., 1993; Strandberg et al., 2004) , and current public health recommendations suggest lower goals for optimal plasma lipid concentrations (Expert Panel, 2001; Grundy et al., 2004) . Therefore, an effect in this normocholesterolemic group was plausible and potentially beneficial from the standpoint of CHD prevention. The present study administered three probiotic capsules once daily (providing a total of 10 9 CFU) for 2 months. This regimen was selected to improve ease of distribution, avoid ingestion of additional calories via the intervention and maximize subject adherence. The dose was intended to maximize the potential for a lipid-lowering effect; however, it may have been insufficient. Although an investigation providing a dose of 10 9 CFU of probiotic bacteria via a daily capsule achieved a hypocholesterolemic effect (Hlivak et al., 2005) , fermented milk studies demonstrating an effect (Agerback et al., 1995; Schaafsma et al., 1998; Bertolami et al., 1999; Xiao et al., 2003) administered 200-300 ml of product containing 10 7 -10 9 CFU
per ml for a total dose of 10 9 -10 11 CFU.
Providing the probiotic bacteria multiple times during the day (especially concomitant with exogenous cholesterol consumption) may have enhanced the possibility of a hypocholesterolemic effect by increasing intestinal exposure to the bacteria. However, other investigations administering capsules three (Lewis and Burmeister, 2005) or four (Lin et al., 1989 ) times daily did not report a decrease in plasma lipids. In contrast, a 1-year study using a single daily capsule containing 10 9 CFU Enterococcus faecium M-74 did demonstrate a decrease in cholesterol, but not until 23 weeks of consumption (Hlivak et al., 2005) . This year-long study may have been complicated by spontaneous dietary changes during the study (nutrient intake was not monitored and lipids tended to decrease throughout the study in the placebo group also and reached a significant drop 4 weeks after cessation of the intervention) but does suggest that longer interventions may warrant further exploration. The preponderance of fermented milk interventions (Agerback et al., 1995; Schaafsma et al., 1998; Bertolami et al., 1999; Xiao et al., 2003) compared to capsule interventions (Hlivak et al., 2005) demonstrating a hypocholesterolemic effect supports the concept that a dairy medium may be the most efficacious route of administering probiotic bacteria. In vitro simulation has suggested that whereas some species of L. and B. lose viability during gastric transit, ingestion with milk proteins improves their tolerance to the pH of upper GI system (Charteris, 1998) . In addition to its potential effect on bacterial viability, milk has been hypothesized to contain components such as 3-hydroxymethyl glutarate and orotic acid that may independently lower cholesterol (Mann, 1977; St-Onge et al., 2000) . Although changes in intestinal microflora were not assessed in the present study, fecal bacteria and enzymes were altered by provision of L. acidophilus DDS-1 and B. longum UABL-14 in a concurrently conducted study in postmenopausal women (Greany et al., 2004) suggesting that the bacteria did remain viable and reach the intestines. If this theory is correct, the lack of hypocholesterolemic effect in this study may be due to the strains of bacteria administered.
The selection of the most promising species and strain of probiotic bacteria for in vivo cholesterol reduction is a challenging and uncertain process. We chose to investigate commercially available probiotic capsules containing L. acidophilus DDS-1 and B. longum UABL-14 for ease in procurement and a history of product safety. Although multiple strains of the species L. acidophilus and B. longum have been shown to possess in vitro bile salt hydrolase activity (Mital and Garg, 1995; Brashears et al., 1998; Tanaka et al., 1999) and to remove cholesterol from a laboratory growth medium by incorporation into the cell membrane or by assimilation, (Noh et al., 1997; Brashears et al., 1998; Dambekodi and Gilliland, 1998) it is possible that the strains we selected did not possess these fundamental characteristics. The lack of hypocholesterolemic effect in a study administering three daily capsules containing 10 9 CFU L. acidophilus DDS-1 and B. longum UABL-14 in mildly hypercholesterolemic postmenopausal women supports this possibility (Greany et al., 2004) . However, as previously demonstrated (Lin et al., 1989; Lewis and Burmeister, 2005) , affirmative in vitro results have not reliably translated to a significant cholesterol-lowering effect in humans. Lin et al. (1989) established the in vitro cholesterol-reducing ability of L. acidophilus ATCC 4962 and L. bulgaricus ATCC 33409 (a commercially available capsule) but failed to show a hypocholesterolemic effect of this product in a large placebocontrolled study in humans. Similarly, Lewis and Burmeister (2005) tested the ability of five L. acidophilus strains isolated from commercial yogurt and selected the most promising strain for administration in a large randomized, placebocontrolled trial, but did not find any change in plasma lipids following the human consumption. Thus, a major barrier to demonstrating a hypocholesterolemic effect in humans is the challenge in determining which of the vast array of probiotic species and strains have the best potential for in vivo effects. Despite the suggestion from in vitro experiments and fermented milk studies that probiotic bacteria can reduce cholesterol and thereby may favorably alter plasma lipids in humans, this study does not support the ability of a dose of 10 9 CFU L. acidophilus strain DDS-1 and Bifidobacterium longum strain UABL-14 consumed in capsule form to lower plasma lipid concentrations in normocholesterolemic young men and women. Future investigations combining probiotic and placebo capsules with probiotic and placebo fermented milk treatments will be valuable in clarifying the role of fermented milk components versus bacteria in the hypocholesterolemic effect of probiotics.
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